|
|
120 Mountain View Boulevard
Basking Ridge, New Jersey 07920 USA
phone:(908) 580-2100
fax:(919) 287-9430
|
|
| Symbol |
private |
| Founded |
2003 |
| Employees |
|
|
|
| www.regadobiosciences.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutic aptamers for cardiovascular indications |
|
| Management |
| David J. Mazzo, Ph.D., President and Chief Executive Officer; Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer; Ellen McDonald. MBA, Senior Vice President, Business Operations and Chief Business Officer; Alexander R. Giaquinto, Ph.D., Senior Vice President of Regulatory Affairs and Quality Assurance Chief Compliance Officer; Chris Rusconi, Ph.D., SVP Discovery/Preclinical Development and Chief Scientific Officer |
| |
|
|
| |
|
| Keywords |
| antithrombotic, percutaneous, thrombosis, anticoagulants, pharmacoeconomic |
|
|
|
|
|
|
| Description |
|
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. Regado�s technology is designed to give physicians the ability to actively and directly control each system�s therapeutic effect providing a safe and unique approach to personalized medicine. The company is focusing its discovery and development efforts on injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. |
|
| Technology / Differentiation |
| Regado�s aptamer-based therapeutics are identified using a proprietary in vitro selection process known as SELEX (Systematic Evolution of Ligands by EXponential enrichment), which the Company in-licensed from Archemix Corporation. In the SELEX process, a vast library of oligonucleotide sequences are incubated with a specific target protein and nucleic acid aptamers with the optimal structural and binding properties are isolated. Aptamers have been discovered that can bind to essentially every class of therapeutic protein target. |
|
|
|
|
|
|
|
Unable to select database |
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members